bpc-157 fda status unapproved warning Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for fda warning unapproved peptides bpc-157

Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

Disruptions in rhythm accelerate cellular aging, impair immune surveillance, and increase disease risk across all major systems of the body

Metabolic rate increase and thermogenesis How tesofensine boosts metabolism: Norepinephrine stimulates beta-adrenergic receptors Activates thermogenesis in brown and white fat Increases basal metabolic rate 5-10% Enhanced fat oxidation (preferential fat burning) Similar to ephedrine effects but stronger Energy expenditure studies: Clinical trials showed increased resting energy expenditure 24-hour metabolic rate elevated 5-10% Translates to ~100-200 extra calories burned daily Combined with appetite suppression = larger deficit Thermogenesis mechanism: Why metabolism boost matters: Creates deficit even without appetite changes Counteracts metabolic adaptation Preserves lean mass better Enhanced fat loss vs muscle loss Different advantage vs GLP-1 agonists Cardiovascular cost: Increased metabolism = increased heart rate Blood pressure elevation Cardiac workload increased Major safety concern Why FDA rejected despite efficacy See best peptides for energy and fat loss peptides

Phase I contracts will have budgets up to $600K, and Phase II Contracts will have budgets up to $3.5M